Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2023 Mar 8

PMID 36883902

Authors

Przemyslaw Grygier

Katarzyna Pustelny

Jakub Nowak

Przemyslaw Golik

Grzegorz M Popowicz

Oliver Plettenburg

Grzegorz Dubin

Filipe Menezes

Anna Czarna

Affiliations

Soon will be listed here.

Abstract

A clinical casein kinase 2 inhibitor, CX-4945 (silmitasertib), shows significant affinity toward the DYRK1A and GSK3β kinases, involved in down syndrome phenotypes, Alzheimer's disease, circadian clock regulation, and diabetes. This off-target activity offers an opportunity for studying the effect of the DYRK1A/GSK3β kinase system in disease biology and possible line extension. Motivated by the dual inhibition of these kinases, we solved and analyzed the crystal structures of DYRK1A and GSK3β with CX-4945. We built a quantum-chemistry-based model to rationalize the compound affinity for CK2α, DYRK1A, and GSK3β kinases. Our calculations identified a key element for CK2α's subnanomolar affinity to CX-4945. The methodology is expandable to other kinase selectivity modeling. We show that the inhibitor limits DYRK1A- and GSK3β-mediated cyclin D1 phosphorylation and reduces kinase-mediated NFAT signaling in the cell. Given the CX-4945's clinical and pharmacological profile, this inhibitory activity makes it an interesting candidate with potential for application in additional disease areas.

Citing Articles

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia.

Li J, Ye C, Li H, Li J Cancer Biol Ther. 2025; 26(1):2457777.

PMID: 39862423 PMC: 11776473. DOI: 10.1080/15384047.2025.2457777.

Structure-Activity Relationship Studies of Tetracyclic Pyrrolocarbazoles Inhibiting Heterotetrameric Protein Kinase CK2.

Kroger L, Borgert S, Lauwers M, Steinkruger M, Jose J, Pietsch M Molecules. 2025; 30(1.

PMID: 39795120 PMC: 11722180. DOI: 10.3390/molecules30010063.

Discovery of 7,9-Dibromo-dihydrodibenzofuran as a Potent Casein Kinase 2 (CK2) Inhibitor: Synthesis, Biological Evaluation, and Structural Studies on /-Isomers.

Rumler H, Schmithals C, Werner C, Bollacke A, Aichele D, Gotz C ACS Pharmacol Transl Sci. 2024; 7(12):3846-3866.

PMID: 39698287 PMC: 11651316. DOI: 10.1021/acsptsci.4c00426.

An experimental and computational investigation of the cyclopentene-containing peptide-derived compounds: focus on pseudo-cyclic motifs via intramolecular interactions.

Bojarska J, Breza M, Borowiecki P, Madura I, Kaczmarek K, Ziora Z R Soc Open Sci. 2024; 11(10):40962.

PMID: 39386982 PMC: 11462612. DOI: 10.1098/rsos.240962.

Protein Kinases in Obesity, and the Kinase-Targeted Therapy.

Engin A Adv Exp Med Biol. 2024; 1460:199-229.

PMID: 39287853 DOI: 10.1007/978-3-031-63657-8_7.

References

Bogusz J, Zrubek K, Rembacz K, Grudnik P, Golik P, Romanowska M . Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors. Sci Rep. 2017; 7(1):13399. PMC: 5645348. DOI: 10.1038/s41598-017-13557-z. View

Lindberg M, Meijer L . Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. Int J Mol Sci. 2021; 22(11). PMC: 8199962. DOI: 10.3390/ijms22116047. View

Son Y, Song J, Kim S, Kim J . Pharmacokinetic characterization of CK2 inhibitor CX-4945. Arch Pharm Res. 2013; 36(7):840-5. DOI: 10.1007/s12272-013-0103-9. View

Agnew C, Liu L, Liu S, Xu W, You L, Yeung W . The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. J Biol Chem. 2019; 294(37):13545-13559. PMC: 6746438. DOI: 10.1074/jbc.RA119.009725. View

Roos K, Wu C, Damm W, Reboul M, Stevenson J, Lu C . OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules. J Chem Theory Comput. 2019; 15(3):1863-1874. DOI: 10.1021/acs.jctc.8b01026. View

Pierre F, Chua P, OBrien S, Siddiqui-Jain A, Bourbon P, Haddach M . Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2010; 54(2):635-54. DOI: 10.1021/jm101251q. View

Stotani S, Giordanetto F, Medda F . DYRK1A inhibition as potential treatment for Alzheimer's disease. Future Med Chem. 2016; 8(6):681-96. DOI: 10.4155/fmc-2016-0013. View

Cohen P, Frame S . The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001; 2(10):769-76. DOI: 10.1038/35096075. View

Buljan M, Ciuffa R, van Drogen A, Vichalkovski A, Mehnert M, Rosenberger G . Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases. Mol Cell. 2020; 79(3):504-520.e9. PMC: 7427327. DOI: 10.1016/j.molcel.2020.07.001. View

10.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

11.

Winn M, Ballard C, Cowtan K, Dodson E, Emsley P, Evans P . Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):235-42. PMC: 3069738. DOI: 10.1107/S0907444910045749. View

12.

Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, OBrien S . CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70(24):10288-98. DOI: 10.1158/0008-5472.CAN-10-1893. View

13.

Bannwarth C, Ehlert S, Grimme S . GFN2-xTB-An Accurate and Broadly Parametrized Self-Consistent Tight-Binding Quantum Chemical Method with Multipole Electrostatics and Density-Dependent Dispersion Contributions. J Chem Theory Comput. 2019; 15(3):1652-1671. DOI: 10.1021/acs.jctc.8b01176. View

14.

Cohen P, Cross D, Janne P . Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021; 20(7):551-569. PMC: 8127496. DOI: 10.1038/s41573-021-00195-4. View

15.

Beurel E, Grieco S, Jope R . Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2014; 148:114-31. PMC: 4340754. DOI: 10.1016/j.pharmthera.2014.11.016. View

16.

Liu F, Liang Z, Wegiel J, Hwang Y, Iqbal K, Grundke-Iqbal I . Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008; 22(9):3224-33. PMC: 2518253. DOI: 10.1096/fj.07-104539. View

17.

Battistutta R, Cozza G, Pierre F, Papinutto E, Lolli G, Sarno S . Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry. 2011; 50(39):8478-88. DOI: 10.1021/bi2008382. View

18.

Yang J, Ten Eyck L, Xuong N, Taylor S . Crystal structure of a cAMP-dependent protein kinase mutant at 1.26A: new insights into the catalytic mechanism. J Mol Biol. 2004; 336(2):473-87. DOI: 10.1016/j.jmb.2003.11.044. View

19.

Kim H, Lee K, Kim A, Choi M, Choi K, Kang M . A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition. Dis Model Mech. 2016; 9(8):839-48. PMC: 5007978. DOI: 10.1242/dmm.025668. View

20.

Reinhard L, Mayerhofer H, Geerlof A, Mueller-Dieckmann J, Weiss M . Optimization of protein buffer cocktails using Thermofluor. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013; 69(Pt 2):209-14. PMC: 3564630. DOI: 10.1107/S1744309112051858. View